Publications

cemka > Publications

Sort publications on year

  • Pharmaco - Epidemiology

    [Which ovarian stimulation to which women: The polycystic ovary syndrome (PCOS)]

    MERVIEL P, BOUEE S, MENARD M, LE MARTELOT MT, ROCHE S, LELIEVRE C, CHABAUD JJ, JACQ C, DRAPIER H, BEAUVILLARD D.

    Gynecol Obstet Fertil Senol ; 2017;45(11):623-631

  • Pharmaco - Epidemiology

    [Self-monitoring of blood glucose in France: data from a national survey]

    GUERCI B, BENHAMOU PY, DURAIN D, BAHLOUL A, JEANBAT V, DETOURNAY B

    Sante Publique ; 2017;29(2):229-240

  • Pharmaco-Economics

    Multiple Source of Information to Characterize the Clinical, Therapeutic Management and Economic Burden of Patients with Multiple Sclerosis in France.

    EPSTEIN J, DETOURNAY B , GUILLEMIN F, DEBOUVERIE M, COUSIN M, TEHARD B, GAROT T, BITOUN L, SOUDANT M , DEPOORTERE PH, PAU D

    Value in Health ; 2017;20(9):a719

  • Public Health and Epidemiology

    De l’intĂ©rĂȘt/de la possibilitĂ© d’utiliser les donnĂ©es de la base Sniiram pour identifier le parcours de soins des enfants dĂ©cĂ©dĂ©s de maladie en Île-de-France en 2012–2013.

    DONIO V, AUVRIGNON A, PELLEGRINO B, COUROUVE L, NISENBAUM N, VIALLE G, GABOLDE M, DETOURNAY B

    Revue D'ÉPIDEMIOLOGIE ET DE SANTE PUBLIQUE ; 2017;65(S3):S126

  • Pharmaco-Economics

    Le coût des hospitalisations pour hypoglycémie en France chez les patients diabétiques de type 2

    DETOURNAY B, HALIMI S, LEVY P, BEC M, TORRETON E, DEJAGER S.

    Revue d'ÉpidĂ©miologie et de SantĂ© Publique ; 2017;65(S3):S137-S138

  • Pharmaco-Economics

    Effect of Multiple Sclerosis on Work Productivity

    DETOURNAY B, COUSIN M, GOURMELEN J, PAU D, PINGUET JM, TEHARD B, COZZONE D

    Value in Health ; 2017;20(9):a725

  • Pharmaco-Economics

    The Direct Cost of Patients With Multiple Sclerosis In France

    DETOURNAY B, COUSIN M, GOURMELEN J, L. BITOUN L, PAU D, COZZONE D, B. TEHARD B

    Value in Health ; 2017;20(9):a721

  • Pharmaco-Economics

    What is the budget impact of a new treatment or new health technology arriving on the market?

    DERVAUX B, LE FUR C, DUBOIS S, JOSSERAN A, DETOURNAY B; participants of round table No. 3 of Giens XXXIII

    Therapie ; 2017;72(1):93-103

  • Pharmaco-Economics

    Quel impact budgĂ©taire pour l’arrivĂ©e d’un nouveau traitement ou d’une nouvelle technologie de santé ?

    DERVAUX B, LE FUR C, DUBOIS S, JOSSERAN A, DETOURNAY B; les participants à la table ronde n(o) 3 de Giens XXXIII.

    Therapie ; 2017;72(1):81-91

  • Pharmaco-Economics

    Economic impact of ulipristal acetate on surgical procedures for uterine fibroids in France

    FERNANDEZ H, JOURDAIN O, VILLEFRANQUE V, LEHMANN M, LAFUMA A, TRANCART M.

    BMJ Open ; 2017;7(9):e015571

  • Pharmaco-Economics

    Burden of severe spondyloarthritis in France: A nationwide assessment of prevalence, associated comorbidities and cost.

    CLAUDEPIERRE P, FAGNANI F, CUKIERMAN G, DE CHALUS T, JOUBERT JM, LAURENDEAU C, GOURMELEN J, BREBAN M

    Joint Bone Spine ; 2019;86(1);69-75

  • Pharmaco - Epidemiology

    Quality of life and utility decrement associated with Clostridium difficile infection in a French hospital setting.

    BARBUT F, GALPERINE T, VANHEMS P, LE MONNIER A, DURAND-GASSELIN B, CANIS F, JEANBAT V, DUBURCQ A, ALAMI S, BENSOUSSAN C, FAGNANI F.

    Health Qual Life Outcomes ; 2019;17(1);6

  • Pharmaco-Economics

    Economic burden of thromboembolic and hemorrhagic complications in non-valvular atrial fibrillation in Algeria (the ELRAGFA study)

    BOUAME M, ALI LAHMAR M, BOUAFIA MT, HAMMOUDI N, CHENTIR MT, ATHMANE MA, KARA S, TRANCART M, YILDIZ L, CHEYNEL J, SOUALMI R.

    J Med Econ ; 2018; 21(12):1213-1220

  • Biometry and database analysis

    Two year continuation rates of contraceptive methods in France: a cohort study from the French national health insurance database.

    AGOSTINI A, GODARD C, LAURENDEAU C, BENMAHMOUD ZOUBIR A, LAFUMA A, LÉVY-BACHELOT L, GOURMELEN J, LINET T.

    Eur J Contracept Reprod Health Care ; 2018;23(6):421-426

  • Public Health and Epidemiology

    Cost-effectiveness analysis of aripiprazole once-monthly versus paliperidone palmitate once-monthly in the treatment of schizophrenia in France.

    GOZLAN G, LECARDEUR L, MONFORT AS, DOZ M, ORTIZ I, LARROUMETS P, LAFUMA A.

    Encephale ; 44:496-503.